NCT02893761

Brief Summary

A database of breast cancer patients was established at Institute Bergonié since the 90s , to assess patients' survival, assess practice, search for prognostic factors.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30,000

participants targeted

Target at P75+ for all trials

Timeline
297mo left

Started Jan 1990

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Jan 1990Dec 2050

Study Start

First participant enrolled

January 1, 1990

Completed
26.6 years until next milestone

First Submitted

Initial submission to the registry

August 18, 2016

Completed
21 days until next milestone

First Posted

Study publicly available on registry

September 8, 2016

Completed
14.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
20 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2050

Last Updated

September 23, 2025

Status Verified

September 1, 2025

Enrollment Period

40.9 years

First QC Date

August 18, 2016

Last Update Submit

September 22, 2025

Conditions

Breast Cancer

Keywords

breast cancersurvival

Outcome Measures

Primary Outcomes (1)

  • Distant metastasis-free survival at 5 years

    5 years

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with breast cancer treated at Bergonie Institute

You may qualify if:

  • Breast cancer
  • Aged 18 years and over
  • First treatment at Bergonie Institute

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Bergonié, Comprehensive Cancer Center

Bordeaux, France

RECRUITING

Related Publications (8)

  • Lhenaff M, Tunon de Lara C, Fournier M, Charitansky H, Brouste V, Mathoulin-Pelissier S, Pinsolles V, Rousvoal A, Bussieres E, Chassaigne F, Croce S, Ben Rejeb H, MacGrogan G. A single-center study on total mastectomy versus skin-sparing mastectomy in case of pure ductal carcinoma in situ of the breast. Eur J Surg Oncol. 2019 Jun;45(6):950-955. doi: 10.1016/j.ejso.2019.01.014. Epub 2019 Jan 17.

    PMID: 30683448BACKGROUND

  • de Mascarel I, MacGrogan G, Debled M, Sierankowski G, Brouste V, Mathoulin-Pelissier S, Mauriac L. D2-40 in breast cancer: should we detect more vascular emboli? Mod Pathol. 2009 Feb;22(2):216-22. doi: 10.1038/modpathol.2008.151. Epub 2008 Sep 26.

    PMID: 18820667BACKGROUND

  • de Mascarel I, Debled M, Brouste V, Mauriac L, Sierankowski G, Velasco V, Croce S, Chibon F, Boudeau J, Debant A, MacGrogan G. Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. Springerplus. 2015 Sep 21;4:528. doi: 10.1186/s40064-015-1297-8. eCollection 2015.

    PMID: 26405647BACKGROUND

  • Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, de Lara CT, Mauriac L, de Mascarel I. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? Cancer. 2010 Jul 1;116(13):3093-101. doi: 10.1002/cncr.25137.

    PMID: 20564641BACKGROUND

  • Morgat C, MacGrogan G, Brouste V, Velasco V, Sevenet N, Bonnefoi H, Fernandez P, Debled M, Hindie E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. J Nucl Med. 2017 Sep;58(9):1401-1407. doi: 10.2967/jnumed.116.188011. Epub 2017 Mar 9.

    PMID: 28280221BACKGROUND

  • Mazroui Y, Mauguen A, Mathoulin-Pelissier S, MacGrogan G, Brouste V, Rondeau V. Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death. Lifetime Data Anal. 2016 Apr;22(2):191-215. doi: 10.1007/s10985-015-9327-y. Epub 2015 May 6.

    PMID: 25944225BACKGROUND

  • Debled M, Auxepaules G, de Lara CT, Garbay D, Brouste V, Bussieres E, Mauriac L, MacGrogan G. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making. Am J Surg. 2014 Nov;208(5):756-763. doi: 10.1016/j.amjsurg.2013.12.032. Epub 2014 Apr 3.

    PMID: 24814311BACKGROUND

  • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, Tunon de Lara C, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N. PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas. Cancer Genet. 2022 Jun;264-265:8-15. doi: 10.1016/j.cancergen.2022.02.008. Epub 2022 Feb 25.

    PMID: 35263698BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Gaetan Mac Grogan, MD

    Institut Bergonié

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gaetan Mac Grogan, MD

CONTACT

+ 33 5 56 33 33 33g.macgrogan@bordeaux.unicancer.fr

Simone Mathoulin-Pélissier, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 18, 2016

First Posted

September 8, 2016

Study Start

January 1, 1990

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2050

Last Updated

September 23, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)